Calcitonin gene related peptide in migraine: Current therapeutics, future implications and potential off-target effects
Research output: Contribution to journal › Review › Research › peer-review
Documents
- Fulltext
Accepted author manuscript, 343 KB, PDF document
Migraine is the second largest cause of years lost to disability globally among all diseases, with a worldwide prevalence over 1 billion. Despite the global burden of migraine, few classes of therapeutics have been specifically developed to combat migraine. After 30 years of translational research, calcitonin gene-related peptide (CGRP) inhibitors have emerged as a promising new tool in the prevention of migraine. Like all new therapeutics; however, we have limited real-world experience and CGRP has several known systemic actions that warrant consideration. This article provides a narrative review of the evidence for CGRP antagonists and summarises the known and potential side effects that should be considered.
Original language | English |
---|---|
Journal | Journal of Neurology, Neurosurgery and Psychiatry |
Volume | 92 |
Issue number | 12 |
Pages (from-to) | 1325-1334 |
ISSN | 0022-3050 |
DOIs | |
Publication status | Published - 2021 |
Bibliographical note
Publisher Copyright:
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
- drug trials, headache, migraine
Research areas
ID: 276702337